Evidence map›Paper›PMID 32999291›Full record

ArticleNature communications2020

Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis.

Lang Rao, Lei Wu, Zhida Liu, Rui Tian, Guocan Yu, Zijian Zhou, Kuikun Yang, Hong-Gang Xiong, Anli Zhang, Guang-Tao Yu and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 163 papers.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 364 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Size-Dependent Immunomodulatory Effects of FeMolecules (Basel, Switzerland) · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. National science review · 2026
    Article
  18. Article
  19. Article
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Lang Rao *Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.
Lei Wu *State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST), Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, 430079, Wuhan, China.
Zhida Liu *Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID http://orcid.org/0000-0002-3980-8440
Rui TianLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.
Guocan YuLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.
Zijian ZhouLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.
Kuikun YangLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA.
Hong-Gang XiongState Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST), Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, 430079, Wuhan, China.
Anli ZhangDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.ORCID http://orcid.org/0000-0001-7847-6541
Guang-Tao YuState Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST), Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, 430079, Wuhan, China.
Wenjing SunCenter for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, China.
Han XuCenter for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, China.
Jingya GuoChinese Academy of Sciences Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, 100101, Beijing, China.
Andrew LiDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21205, USA.
Hongmin ChenCenter for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, 361102, Xiamen, China. hchen@xmu.edu.cn.
Zhi-Jun SunState Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST), Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, 430079, Wuhan, China. sunzj@whu.edu.cn.ORCID http://orcid.org/0000-0003-0932-8013
Yang-Xin FuDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA. yang-xin.fu@utsouthwestern.edu.ORCID http://orcid.org/0000-0002-4809-825X
Xiaoyuan ChenLaboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, 20892, USA. chen9647@gmail.com.ORCID http://orcid.org/0000-0002-9622-0870
National Institutes of Health · USWuhan University · CNXiamen University · CNThe University of Texas Southwestern Medical Center · USChinese Academy of Sciences · CNJohns Hopkins University · USSouthwestern Medical Center · US

Funding

Laboratory of Molecular Imaging and NanomedicineZIAEB000073 · NIBIB · NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING · PI CHEN, XIAOYUAN · 2010 to 2020
$32.8M
Intramural NIH HHS ZIA EB000073
6 · The paper itself

Abstract

Effectively activating macrophages against cancer is promising but challenging. In particular, cancer cells express CD47, a 'don't eat me' signal that interacts with signal regulatory protein alpha (SIRPα) on macrophages to prevent phagocytosis. Also, cancer cells secrete stimulating factors, which polarize tumor-associated macrophages from an antitumor M1 phenotype to a tumorigenic M2 phenotype. Here, we report that hybrid cell membrane nanovesicles (known as hNVs) displaying SIRPα variants with significantly increased affinity to CD47 and containing M2-to-M1 repolarization signals can disable both mechanisms. The hNVs block CD47-SIRPα signaling axis while promoting M2-to-M1 repolarization within tumor microenvironment, significantly preventing both local recurrence and distant metastasis in malignant melanoma models. Furthermore, by loading a stimulator of interferon genes (STING) agonist, hNVs lead to potent tumor inhibition in a poorly immunogenic triple negative breast cancer model. hNVs are safe, stable, drug loadable, and suitable for genetic editing. These properties, combined with the capabilities inherited from source cells, make hNVs an attractive immunotherapy.

Indexed as

AnimalsCD47 AntigenCell-Derived MicroparticlesCell Line, TumorDisease Models, AnimalFemaleHEK293 CellsHumansImmunotherapyMacrophage ActivationMacrophagesMelanomaMembrane ProteinsMiceNanoparticlesNeoplasm Recurrence, LocalCD47 AntigenCd47 protein, mousecyclic guanosine monophosphate-adenosine monophosphateMembrane ProteinsNucleotides, CyclicReceptors, ImmunologicSirpa protein, mouseSting1 protein, mouseSTING Protein

Identifiers

PMID32999291
PMCPMC7527506
OpenAlexW3091696020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.